An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.
Plant-derived vaccines represent an attractive strategy for cancer immunotherapy due to their relative safety and cost-effectiveness. We evaluated the anti-tumour activity of a Nicotiana benthamiana produced vaccine candidate based on the non-transforming E7 protein of HPV-16 fused to beta-1,3-1,4-glucanase of Clostridium thermocellum. Two doses of vaccine at two week intervals were administered to groups of C57BL/6 mice starting 3 or 6 days after challenge with tumourigenic E7-expressing TC-1* cells. Inhibition of tumour growth and increased survival was observed in both groups treated with vaccine. These data suggest the potential of plants as a platform for producing therapeutic vaccines.
Venuti
Aldo
A
Regina Elena Cancer Institute, Laboratory of Virology, Via delle Messi d'Oro 156, 00158 Rome, Italy. venuti@ifo.it
Massa
Silvia
S
Mett
Vadim
V
Vedova
Laura Dalla
LD
Paolini
Francesca
F
Franconi
Rosella
R
Yusibov
Vidadi
V
D000818:Animals; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000517:prevention & control*; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D014026:Nicotiana / Q000235:genetics; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; C059731:oncogene protein E7, Human papillomavirus type 16